- Home
- ATOS vs PCF Comparison
ATOS vs PCF Comparison
Compare ATOS & PCF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ATOS
- PCF
- Stock Information
- Founded
- ATOS 2009
- PCF 1987
- Country
- ATOS United States
- PCF United States
- Employees
- ATOS N/A
- PCF N/A
- Industry
- ATOS Biotechnology: Pharmaceutical Preparations
- PCF Trusts Except Educational Religious and Charitable
- Sector
- ATOS Health Care
- PCF Finance
- Exchange
- ATOS Nasdaq
- PCF Nasdaq
- Market Cap
- ATOS 120.4M
- PCF 116.8M
- IPO Year
- ATOS 2012
- PCF N/A
- Fundamental
- Price
- ATOS $0.86
- PCF $6.26
- Analyst Decision
- ATOS Strong Buy
- PCF
- Analyst Count
- ATOS 3
- PCF 0
- Target Price
- ATOS $6.25
- PCF N/A
- AVG Volume (30 Days)
- ATOS 1.3M
- PCF 74.8K
- Earning Date
- ATOS 11-12-2025
- PCF 01-01-0001
- Dividend Yield
- ATOS N/A
- PCF 10.90%
- EPS Growth
- ATOS N/A
- PCF N/A
- EPS
- ATOS N/A
- PCF N/A
- Revenue
- ATOS N/A
- PCF N/A
- Revenue This Year
- ATOS N/A
- PCF N/A
- Revenue Next Year
- ATOS N/A
- PCF N/A
- P/E Ratio
- ATOS N/A
- PCF N/A
- Revenue Growth
- ATOS N/A
- PCF N/A
- 52 Week Low
- ATOS $0.55
- PCF $5.71
- 52 Week High
- ATOS $1.66
- PCF $6.96
- Technical
- Relative Strength Index (RSI)
- ATOS 39.96
- PCF 43.36
- Support Level
- ATOS $0.86
- PCF $6.17
- Resistance Level
- ATOS $0.91
- PCF $6.30
- Average True Range (ATR)
- ATOS 0.05
- PCF 0.05
- MACD
- ATOS -0.02
- PCF 0.00
- Stochastic Oscillator
- ATOS 4.01
- PCF 47.22
About ATOS Atossa Therapeutics Inc.
Atossa Therapeutics Inc is a clinical stage biopharmaceutical company developing proprietary medicines in areas of unmet medical need in oncology. It focuses on the development of novel therapeutics and delivery methods for the treatment of breast cancer, other breast conditions and COVID-19. The company's drug under development for breast cancer and other breast conditions is Endoxifen. Its two COVID-19 drugs under development are AT-H201, to improve lung function of moderate to severely ill, hospitalized COVID-19 patients by inhalation; and AT-301, a nasal spray for COVID-19 patients for at-home use.
About PCF High Income Securities Fund
High Income Securities Fund is a closed-end management investment company. Its primary objective is to provide high current income and capital appreciation is the secondary objective. The Fund pursues its objective primarily by investing in both convertible bonds and convertible preferred stocks. The Fund also invests significantly in high-yielding non-convertible securities with the potential for capital appreciation.